Virtus ETF Advisers LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Virtus ETF Advisers LLC

$206 Million
Q3 2024

A detailed history of Virtus ETF Advisers LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 3,478 shares of ARWR stock, worth $67,925. This represents 0.03% of its overall portfolio holdings.

Number of Shares

3,478

Previous 3,416 1.81%

Holding current value

$67,925

Previous $88,000 23.86%

% of portfolio

0.03%

Previous 0.04%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.36 - $29.54 $1,200 - $1,831	62 Added 1.81%	3,478 $67,000
Q2 2024 Aug 14, 2024	BUY	$21.87 - $28.24 $8,419 - $10,872	385 Added 12.7%	3,416 $88,000
Q1 2024 May 15, 2024	SELL	$27.21 - $39.48 $5,768 - $8,369	-212 Reduced 6.54%	3,031 $86,000
Q4 2023 Feb 15, 2024	BUY	$21.2 - $31.03 $9,412 - $13,777	444 Added 15.86%	3,243 $99,000
Q3 2023 Nov 07, 2023	SELL	$26.2 - $36.08 $7,283 - $10,030	-278 Reduced 9.03%	2,799 $75,000
Q2 2023 Aug 14, 2023	SELL	$25.16 - $41.38 $25 - $41	-1 Reduced 0.03%	3,077 $109,000
Q1 2023 May 15, 2023	SELL	$23.68 - $38.51 $28,084 - $45,672	-1,186 Reduced 27.81%	3,078 $78,000
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $14,616 - $21,172	522 Added 13.95%	4,264 $172,000
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $711 - $1,159	24 Added 0.65%	3,742 $124,000
Q2 2022 Aug 12, 2022	BUY	$27.79 - $50.61 $40,573 - $73,890	1,460 Added 64.66%	3,718 $131,000
Q1 2022 May 16, 2022	SELL	$39.62 - $69.97 $5,626 - $9,935	-142 Reduced 5.92%	2,258 $104,000
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $174 - $247	-3 Reduced 0.12%	2,400 $159,000
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $7,414 - $10,789	-127 Reduced 5.02%	2,403 $150,000
Q2 2021 Aug 10, 2021	SELL	$62.15 - $90.32 $91,733 - $133,312	-1,476 Reduced 36.84%	2,530 $210,000
Q1 2021 May 17, 2021	BUY	$61.35 - $90.47 $4,171 - $6,151	68 Added 1.73%	4,006 $266,000
Q4 2020 Feb 12, 2021	SELL	$43.82 - $85.37 $240,396 - $468,339	-5,486 Reduced 58.21%	3,938 $302,000
Q3 2020 Nov 13, 2020	SELL	$33.21 - $51.27 $42,542 - $65,676	-1,281 Reduced 11.97%	9,424 $406,000
Q2 2020 Aug 05, 2020	BUY	$26.12 - $43.27 $138,540 - $229,504	5,304 Added 98.2%	10,705 $462,000
Q1 2020 May 14, 2020	SELL	$20.56 - $63.12 $16,345 - $50,180	-795 Reduced 12.83%	5,401 $155,000
Q4 2019 Feb 13, 2020	SELL	$28.14 - $73.01 $100,994 - $262,032	-3,589 Reduced 36.68%	6,196 $393,000
Q3 2019 Nov 12, 2019	SELL	$26.26 - $34.86 $14,311 - $18,998	-545 Reduced 5.28%	9,785 $276,000
Q2 2019 Aug 13, 2019	SELL	$17.43 - $28.82 $135,779 - $224,507	-7,790 Reduced 42.99%	10,330 $274,000
Q1 2019 May 14, 2019	SELL	$12.05 - $20.18 $25,799 - $43,205	-2,141 Reduced 10.57%	18,120 $333,000
Q4 2018 Feb 05, 2019	SELL	$10.74 - $19.7 $207,120 - $379,914	-19,285 Reduced 48.77%	20,261 $252,000
Q3 2018 Nov 14, 2018	SELL	$14.0 - $20.3 $406,574 - $589,532	-29,041 Reduced 42.34%	39,546 $758,000
Q2 2018 Aug 10, 2018	BUY	$6.37 - $14.02 $436,899 - $961,589	68,587 New	68,587 $933,000

Others Institutions Holding ARWR

# of Institutions

294

Shares Held

90.8M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.07B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.

Account

Virtus ETF Advisers LLC Arrowhead Pharmaceuticals, Inc. Transaction History